Ramucirumab

Ramucirumab Reactions 1680, p294 - 2 Dec 2017 Wound healing failure: case report A 51-year-old man developed wound healing failure following the therapy with ramucirumab. The man had metastatic stage IV lung adenocarcinoma. He had received carboplatin, pemetrexed and bevacizumab. However, due to disease progression, his medication was altered to docetaxel and ramucirumab 10 mg/kg [route not stated]. After two weeks of cycle 1, he underwent right jugular port placement for the adenocarcinoma. Six days later, he received another cycle of docetaxel and ramucirumab using a peripheral access, since the chest wall site was noted not to have healed. A third cycle of docetaxel and ramucirumab was administered peripherally after one month of the port placement. The chest incision site was noted to be tender with incomplete healing. One week later, the port site and venotomy incisions were not well apposed, with mild exudate from the incision. It was then revealed that the wound healing failure was due to the ramucirumab therapy. The man’s ramucirumab therapy was discontinued. He then received treatment with cefalexin. After one month, there was slight improvement in the port reservoir site, but the venotomy site was open and had not improved. The port was then removed and then a new port placed on the left side. Author comment: "In this case, the poor wound healing likely represents an adverse effect of ramucirumab". Zhan C, et al. Wound Healing Failure Following Venous Access Chest Port Placement Associated with Ramucirumab Therapy. Cardiovascular and Interventional Radiology 40: 1804-1806, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1007/s00270-017-1752-8 - USA 803285097 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ramucirumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/ramucirumab-DE2qdnD7KQ
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39225-5
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial